In contrast, the results from the ATTIRE RCT (14 days of albumin treatment to achieve serum albumin levels of at least 35 g/L vs. standard care in patients with AD and serum albumin levels of less than 30 g/L) were recently published and indicated no beneficial effect of albumin on the primary endpoint (composite of infection, renal dysfunction, or mortality between days 3 and 15 after treatment)82. This evidence concerns the gene ALB and Abnormal renal physiology.